Abstract:BackgroundThe role of platelet–lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio (NLR) as independent prognostic markers in different tumors is well established. However, there is a limited review of the potential of NLR and PLR as predictors of treatment outcomes from immune checkpoint inhibitors (ICIs).ObjectiveTo establish a correlation between NLR and PLR and the potential of clinical benefit from ICIs.MethodsThe literature search was performed for studies that reported the association between NLR, PLR, and treatment outcomes among cancer patients treated with ICIs. The outcomes of interest were objective response rate (ORR), disease control rate (DCR), and progressive disease (PD). ORR was the summation of patients who achieved complete response and partial response. DCR included patients who achieved stable disease. PD was the proportion of patients who progressed, relapsed, or discontinued the treatment. Statistical analysis was performed using the STATA 12.0 package. Heterogeneity was determined by the I2 value. Quality assessment was performed using the Newcastle–Ottawa Scale. Egger’s test was used to establish publication bias and sensitivity analysis.ResultsA total of 40 papers that met the inclusion criteria were included in the systematic review. However, only 17 studies were used in the meta-analysis to determine the correlation between NLR, PLR, and treatment response. We found that treatment with ICIs and monitoring of outcomes and adverse events using PLR and NLR parameters have been studied in different tumors. Our analysis showed that low NLR correlated with higher ORR (OR = 0.62 (95% CI 0.47–0.81, p = 0.001) and higher DCR (OR = 0.23, 95% CI 0.14–0.36, p < 0.001). Higher NLR predicted a higher probability of PD (OR = 3.12, 95% CI 1.44, 6.77, p = 0.004). Similarly, low PLR correlated with higher ORR (OR = 0.69, 95% CI 0.5, 0.95, p = 0.025). Generally, patients with low NLR and PLR were more likely to achieve clinical benefit and better response (p-value < 0.001). Meanwhile, patients with high ratios were more likely to progress (p-value < 0.005), although there was significant heterogeneity among studies. There was no significant publication bias observed.ConclusionThe study showed that high NLR and PLR either at baseline or during treatment is associated with poorer treatment outcome. Therefore, these ratios can be utilized in clinical practice with other markers to determine treatment efficacy from immunotherapy.

Utility of neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, mean platelet volume–platelet count ratios: Diagnostic and prognostic markers in patients with hepatocellular carcinoma, prostate carcinoma, stomach carcinoma, and aplastic anemia

Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review

Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio As Potential Predictive Markers of Treatment Response in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Clinical Application Values of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Multiple Cancers

Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios May Aid in Identifying Patients with Non-Small Cell Lung Cancer and Predicting Tumor-Node-Metastasis Stages

Predictive Value of Neutrophil-To-Lymphocyte Ratio (nlr), Platelet-To-Lymphocyte Ratio (plr), and Lymphocyte-To-Monocyte Ratio (lmr) for Patients with Advanced Hbv-Associated Hcc.

Role of Pre-Operative of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in Prognosis of Hepatocellular Carcinoma

Prognostic Significance of Pre-Treatment Neutrophil–Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Head and Neck Malignancies

Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer

Usefulness of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Hormone-Receptor-negative Breast Cancer.

Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer

Prognostic significance of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in association with clinical parameters in acute leukemia patients

Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios As Independent Predictors of T Stages in Hilar Cholangiocarcinoma.

Preoperative Platelet-Lymphocyte Ratio is a Superior Prognostic Biomarker to Other Systemic Inflammatory Response Markers in Non-Small Cell Lung Cancer

Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma

Assessment of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and mean platelet volume levels in oral squamous cell carcinoma and their correlation with histological grading and TNM staging

Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study.

The Prognostic Value of Peripheral Inflammatory Cell Ratios in Patients with Cervical Cancer After Radiotherapy

Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis

Clinical Significance of Pre-Operative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio As Prognostic Factors for Patients with Colorectal Cancer.

Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer